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Background: Glioblastoma (GBM) is a highly aggressive brain tumor which displays innate resistance to multiple
treatment modalities. Previous studies have shown that the proteasome plays a vital role in the physiology of GBM,
and that proteasome inhibition can be used as a strategy for treating malignant gliomas. Marizomib is a second
generation irreversible proteasome inhibitor which has a more lipophilic structure, suggestive of potential for
penetration of the blood brain barrier (BBB), and has a broader and more prolonged inhibition proteasome inhibition
profile than bortezomib and carfilzomib, the two proteasome inhibitors approved for treatment of multiple myeloma.
While bortezomib and carfilzomib have little-no activity against malignant gliomas, marizomib could be a novel
therapeutic strategy for primary brain tumors. Marizomib is presently in clinical trial for multiple myeloma. Methods:
The in vitro antitumor activity of marizomib was studied in human glioma lines U251 and D54. The ability of marizomib
to cross the BBB and regulate proteasome activities was evaluated in cynomolgus monkeys and rats. The anti-tumor
effect of marizomib in vivo was tested in an orthotopic xenograft model of human GBM. Results: Marizomib inhibited
survival of U251 and D54 by ~90% at 60nM and markedly decreased GBM cell migration and invasion. While marizomib
induced increased free radical production and apoptosis, the reactive oxygen species quenching agent NAC blocked
these effects. In rats, marizomib distributed into the brain at 30% of blood levels, and the monkey studies revealed
robust baseline chymotrypsin-like (CT-L) proteasome activity in brain tissue that was significantly inhibited ( > 30%) in
animals treated with marizomib. Similar effects were seen against the caspase-like activity. Encouragingly, mice
treated with marizomib survived significantly longer than the control animals (p< 0.05). Conclusions: These preclinical
studies demonstrate that marizomib can cross the BBB and inhibit proteasome activity in primate brain, and elicit a
significant anti-tumor effect in a rodent intracranial model of malignant gliomas. Marizomib is in Phase 1 clinical
testing for malignant gliomas.
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